(+) Proteostasis Therapeutics ( PTI ), which was up more than 19% after the biopharmaceutical company said it has entered a worldwide, exclusive license agreement with Genentech for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.
(+) Evofem Biosciences ( EVFM ) was more than 13% higher as the company said its phase 3 trial of Amphora birth control met its primary endpoint.
(+) Brainstorm Cell Therapeutics ( BCLI ) was up more than 5% after it announced an investigational new drug application to initiate a phase 2 clinical trial of NurOwn for the treatment of progressive multiple sclerosis ( MS ) has been accepted by the US regulator.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.
Go to Appearance > Customize > Subscribe Pop-up to set this up.
Wealth Empire Newsletter
Register now for free updates and alerts
Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.